Form 4: Vaxcyte Director Olivier Brandicourt Reports Acquisition of Shares and Stock Options

Vaxcyte, Inc. Director Olivier Brandicourt has reported the acquisition of 1,148 shares of common stock through restricted stock units and 5,807 stock options, effective June 12, 2025.

Summary

• Olivier Brandicourt, a Director of Vaxcyte, Inc. (PCVX), reported an acquisition of securities.
• The transaction date for the acquisitions was June 12, 2025.
• Mr. Brandicourt acquired 1,148 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• He also acquired 5,807 Stock Options with an exercise price of $34.46.
• Both the RSUs and stock options are subject to vesting, which will occur on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on Mr. Brandicourt's continuous service through such date.

Sentiment

Score: 7

Explanation: The acquisition of additional equity by a director typically signals confidence in the company's future performance and aligns management interests with shareholders.

Positives

• Director Olivier Brandicourt acquired additional equity in Vaxcyte, Inc., signaling continued alignment with shareholder interests and confidence in the company's future.
• The acquisition of 1,148 Restricted Stock Units (RSUs) and 5,807 stock options increases the director's stake in the company, reinforcing long-term commitment.

Negatives

• N/A

Risks

• N/A

Future Outlook

The vesting schedule for the acquired RSUs and stock options extends to June 12, 2026, or the day prior to the next annual meeting of stockholders, indicating a continued long-term commitment from the director.

Management Comments

• N/A

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends beyond the specific equity compensation granted to a director at Vaxcyte, Inc.

Comparison to Industry Standards

• N/A

Management Changes

Corporate Governance

Legal Proceedings

• N/A

Related Party Transactions

• Acquisition of 1,148 Restricted Stock Units (RSUs) and 5,807 stock options by Olivier Brandicourt, a Director of Vaxcyte, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to increased equity ownership.
• Employees: No direct impact mentioned.

Next Steps

• Vesting of 1,148 Restricted Stock Units (RSUs) on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• Vesting of 5,807 stock options on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, insider transaction, stock options, restricted stock units, director compensation, equity acquisition